Shares of Senesco Technologies Inc. (NYSE:ELOX) have earned a consensus broker rating score of 1.50 (Buy) from the four analysts that provide coverage for the stock, Zacks Investment Research reports. One research analyst has rated the stock with a hold recommendation and three have given a strong buy recommendation to the company. Senesco Technologies’ rating score has declined by 7.1% in the last three months as a result of various analysts’ upgrades and downgrades.
Brokerages have set a 1-year consensus price target of $14.00 for the company and are anticipating that the company will post ($0.39) EPS for the current quarter, according to Zacks. Zacks has also given Senesco Technologies an industry rank of 90 out of 256 based on the ratings given to its competitors.
ELOX traded up $0.06 on Tuesday, reaching $6.24. The stock had a trading volume of 31,600 shares, compared to its average volume of 54,511. Senesco Technologies has a 12-month low of $5.14 and a 12-month high of $18.50. The business’s 50-day moving average price is $8.30 and its two-hundred day moving average price is $10.51.
About Senesco Technologies
Eloxx Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, focuses on discovering and developing novel therapeutics for the treatment of rare and ultra-rare premature stop codon diseases. Its lead program is ELX-02, which is in Phase I clinical trial, which focuses on the treatment of cystic fibrosis and cystinosis patients with diagnosed nonsense mutations.
Further Reading: Growth and Income Funds
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Senesco Technologies Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Senesco Technologies and related companies with MarketBeat.com's FREE daily email newsletter.